{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:16:23Z","timestamp":1787498183666,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11239-021-02578-1","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T18:15:43Z","timestamp":1633630543000},"page":"690-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism"],"prefix":"10.1007","volume":"53","author":[{"given":"Vickie","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kaplovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2406","authenticated-orcid":false,"given":"Jameel","family":"Abdulrehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"issue":"2","key":"2578_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295\u2013306","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2578_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.16308","volume":"189","author":"DRJ Arachchillage","year":"2020","unstructured":"Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M et al (2020) Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants. Br J Haematol. 189(2):212\u2013215","journal-title":"Br J Haematol."},{"issue":"10","key":"2578_CR3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296\u20131304","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"2578_CR4","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","volume":"124","author":"C Chai-Adisaksopha","year":"2014","unstructured":"Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124(15):2450\u20132458","journal-title":"Blood"},{"issue":"5","key":"2578_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","volume":"35","author":"CH Yeh","year":"2015","unstructured":"Yeh CH, Hogg K, Weitz JI (2015) Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol 35(5):1056\u20131065","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"2578_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365\u20131371","journal-title":"Blood"},{"issue":"10","key":"2578_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-0291","volume":"171","author":"J Ordi-Ros","year":"2019","unstructured":"Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomo A et al (2019) Rivaroxaban versus Vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 171(10):685\u2013694","journal-title":"Ann Intern Med"},{"issue":"9","key":"2578_CR8","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/jth.14935","volume":"18","author":"S Zuily","year":"2020","unstructured":"Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V et al (2020) Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 18(9):2126\u20132137","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2578_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","volume":"7","author":"V Pengo","year":"2009","unstructured":"Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7(10):1737\u20131740","journal-title":"J Thromb Haemost"},{"key":"2578_CR10","volume-title":"Laboratory testing for the Lupus anticoagulant","author":"Institute CaLS Document H-60 A","year":"2014","unstructured":"Institute CaLS Document H-60 A (2014) Laboratory testing for the Lupus anticoagulant. Institute CaLS Document H-60 A, Wayne"},{"issue":"8","key":"2578_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/ket126","volume":"52","author":"R Nayfe","year":"2013","unstructured":"Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology 52(8):1358\u20131367","journal-title":"Rheumatology"},{"issue":"7","key":"2578_CR12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jth.13336","volume":"14","author":"C Kearon","year":"2016","unstructured":"Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA et al (2016) Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 14(7):1480\u20131483","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2578_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"key":"2578_CR14","unstructured":"Dean AGS, Soe KM (2013) OpenEpi MM: Open source epidemiologic statistics for public health, version. www.OpenEpi.com"},{"issue":"10","key":"2578_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","volume":"17","author":"V Dufrost","year":"2018","unstructured":"Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX et al (2018) Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 17(10):1011\u20131021","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2578_CR16","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","volume":"3","author":"H Cohen","year":"2016","unstructured":"Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S et al (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial. Lancet Haematol 3(9):e426\u2013e436","journal-title":"Lancet Haematol"},{"key":"2578_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40814-020-00594-1","volume":"6","author":"K Legault","year":"2020","unstructured":"Legault K, Blostein M, Carrier M, Khan S, Schulman S, Shivakumar S et al (2020) A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud 6:52","journal-title":"Pilot Feasibility Stud"},{"key":"2578_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17634","author":"AJ Doyle","year":"2021","unstructured":"Doyle AJ, Hunt BJ, Danaee A, Ling G, Desborough MJ, Luo P et al (2021) Direct oral anticoagulant use in patients with antiphospholipid syndrome and unprovoked venous thromboembolism: a single centre experience. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.17634","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02578-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02578-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02578-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T04:12:37Z","timestamp":1649391157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02578-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2578"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02578-1","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"19 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors do not declare any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}